Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Dazodalibep in Sjogren Syndrome With Moderate-to-Severe Symptoms
jRCT2061240009Phase 3Active, not recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of dazodalibep in Sjögren's syndrome (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Change from baseline in DASPRI score or ESSPRI score at Week 48. Started Aug 2024; status: active, not recruiting.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2061240009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240009.